What are the generic medicines for Glasdegib?

Glasdegib is a Hedgehog signaling pathway inhibitor, mainly used to treat newly diagnosed patients with acute myeloid leukemia (AML) who are not suitable for intensive induction chemotherapy. It blocks the Hedgehog pathway by inhibiting the Smoothened (SMO) protein, thereby reducing the proliferation and survival of leukemia stem cells. The drug was developed by Pfizer and approved in many countries around the world under the trade name Daurismo. However, there are currently no generic drugs of Glasgibb on the market globally. This is mainly due to the fact that its patent protection has not expired, and the AML treatment market is relatively special, and the entry threshold for generic drug companies is high.

In China, the original drug of Glasgib has not yet been launched on the market, so its pricing, medical insurance coverage and other information are still unclear. At present, if domestic patients need to use Glassgib, they usually choose to purchase it from overseas channels, such as the European version or the American version of Daurismo. According to the pricing situation in overseas markets, the price of 30 tablets of Glass Gibb with 100mg specification is about RMB 80,000-90,000. The specific price may fluctuate due to exchange rate changes, supply and demand conditions and different purchasing channels.

The development of generic drugs often involves the expiration of the originator drug's patent and the assessment of market demand. Glasgibb's patent is expected to gradually expire in the next few years, and generic drug companies may begin to develop and market generic versions at that time. Globally, India and China are often important countries in the production of generic drugs, and Indian pharmaceutical companies in particular are good at quickly launching low-cost alternatives after patent expiration. At present, although there is no generic version of Glasgib on the market, if generic drugs enter the market in the future, it may significantly reduce the cost of treatment and benefit more AML patients.

Reference materials:https://en.wikipedia.org/wiki/Glasdegib